| scholarly article | Q13442814 |
| P356 | DOI | 10.1001/ARCHINTE.1991.00400100100017 |
| P698 | PubMed publication ID | 1929691 |
| P2093 | author name string | Davis CS | |
| Chrischilles EA | |||
| Wallace RB | |||
| Butler CD | |||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | osteoporosis | Q165328 |
| P304 | page(s) | 2026-2032 | |
| P577 | publication date | 1991-10-01 | |
| P1433 | published in | JAMA Internal Medicine | Q177428 |
| P1476 | title | A model of lifetime osteoporosis impact. | |
| P478 | volume | 151 |
| Q34300668 | 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. |
| Q40471619 | A model of osteoporosis impact in Switzerland 2000-2020. |
| Q51428150 | A pragmatic randomised controlled trial of the effectiveness and cost-effectiveness of screening older women for the prevention of fractures: rationale, design and methods for the SCOOP study. |
| Q35779222 | A review of teriparatide and its clinical efficacy in the treatment of osteoporosis |
| Q34566371 | A systematic review of the outcomes of osteoporotic fracture patients after hospital discharge: morbidity, subsequent fractures, and mortality |
| Q71229209 | Age-related hip fractures in men: clinical spectrum and short-term outcomes |
| Q36953785 | Allicin inhibits oxidative stress-induced mitochondrial dysfunction and apoptosis by promoting PI3K/AKT and CREB/ERK signaling in osteoblast cells |
| Q51916226 | An approach for identifying postmenopausal women age 50-64 years at increased short-term risk for osteoporotic fracture. |
| Q51242741 | Ankle fractures have features of an osteoporotic fracture. |
| Q34307115 | Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: Synopsis of a WHO report |
| Q40881283 | Assessment of the older woman. |
| Q38696900 | Can we induce osteoporosis in animals comparable to the human situation? |
| Q36454421 | Canadian Consensus Conference on osteoporosis, 2006 update. |
| Q36536188 | Cardiovascular disease and osteoporosis: balancing risk management. |
| Q27016636 | Chronic proton pump inihibitor therapy and calcium metabolism |
| Q41597027 | Clinical consequences of vertebral fractures |
| Q37862933 | Clinical strategies to address patients' concerns in osteoporosis management with bisphosphonates |
| Q67570064 | Commentary: women, research, and the National Institutes of Health |
| Q30988363 | Community based intervention to optimize osteoporosis management: randomized controlled trial |
| Q37033979 | Community-based randomised controlled trial evaluating falls and osteoporosis risk management strategies |
| Q47598003 | Comparative risks for cancer associated with use of calcitonin, bisphosphonates or selective estrogen receptor modulators among osteoporosis patients: a population-based cohort study. |
| Q44223490 | DXA and pQCT predict pertrochanteric and not femoral neck fracture load in a human side-impact fracture model |
| Q42805731 | Deoxyactein stimulates osteoblast function and inhibits bone-resorbing mediators in MC3T3-E1 cells |
| Q34667487 | Dietary acid load is not associated with lower bone mineral density except in older men |
| Q44458339 | Dietary acid load, kidney function, osteoporosis, and risk of fractures in elderly men and women |
| Q34655530 | Distal radius fractures in older women: a 10-year follow-up study of descriptive characteristics and risk factors. The study of osteoporotic fractures |
| Q33788945 | Do bisphosphonates reduce the risk of osteoporotic fractures? An evaluation of the evidence to date. |
| Q34404374 | Downturn in hip fracture incidence |
| Q34508441 | Dual-energy X-ray absorptiometry in clinical practice: application and interpretation of scans beyond the numbers |
| Q33394026 | Effect of combined treatment with alendronate and calcitriol on femoral neck strength in osteopenic rats |
| Q36178344 | Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies |
| Q51546339 | Effect of strontium ranelate on fracture healing in the osteoporotic rats |
| Q33760576 | Effects of teriparatide versus alendronate for treatment of postmenopausal osteoporosis: A meta-analysis of randomized controlled trials |
| Q38067477 | Endocrinology of menopause. |
| Q34671295 | Epidemiology and outcomes of osteoporotic fractures |
| Q40807463 | Epidemiology and public health impact of osteoporosis |
| Q40475922 | Epidemiology of osteoporosis. Implications for drug therapy. |
| Q35007963 | Estimation of 10-year probability bone fracture in a selected sample of Palestinian people using fracture risk assessment tool |
| Q43166167 | Evaluation of the effect of 4 months of risedronate therapy on femoral strength using femoral strength analysis tools |
| Q40437539 | Evaluation of therapeutic efficacy in osteoporosis |
| Q36040681 | Evaluation of trabecular microarchitecture in nonosteoporotic postmenopausal women with and without fracture. |
| Q36056975 | Evidence of sustained vertebral and nonvertebral antifracture efficacy with ibandronate therapy: a systematic review |
| Q40506138 | Expected lifetime numbers, risks, and burden of osteoporotic fractures for 50-year old Chinese women: a discrete event simulation incorporating FRAX. |
| Q92691332 | Fracture prediction, imaging and screening in osteoporosis |
| Q37077317 | Geographic differences in fractures among women |
| Q51975387 | Hip fracture outcomes: quality of life and functional status in older adults living in the community. |
| Q41104614 | Hip fractures in the elderly: a world-wide projection |
| Q44469996 | Institutionalization following incident non-traumatic fractures in community-dwelling men and women |
| Q92702022 | Lactose Intolerance and Bone Health: The Challenge of Ensuring Adequate Calcium Intake |
| Q34495992 | Laser-Supported Dual Energy X-Ray Absorptiometry (DXL) Compared to Conventional Absorptiometry (DXA) and to FRAX as Tools for Fracture Risk Assessments |
| Q34884415 | Levothyroxine dose and risk of fractures in older adults: nested case-control study. |
| Q34272056 | Long-term safety and efficacy of raloxifene in the prevention and treatment of postmenopausal osteoporosis: an update |
| Q50802329 | Magnetic resonance spectroscopic analysis of multifidus muscles lipid content and association with spinopelvic malalignment in chronic low back pain. |
| Q39405573 | Magnolol protects osteoblastic MC3T3-E1 cells against antimycin A-induced cytotoxicity through activation of mitochondrial function |
| Q37337113 | Management of osteoporosis in the aging male: focus on zoledronic acid |
| Q74787564 | Managing patients with complications of osteoporosis |
| Q50860772 | MiR-142-5p promotes bone repair by maintaining osteoblast activity. |
| Q78399026 | Minimally invasive options for the treatment of osteoporotic vertebral compression fractures |
| Q46592923 | Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study |
| Q40202424 | Mortality After Atypical Femoral Fractures: A Cohort Study |
| Q92335792 | Multifidus Muscles Lipid Content Is Associated with Intervertebral Disc Degeneration: A Quantitative Magnetic Resonance Imaging Study |
| Q33785411 | New bisphosphonates in the treatment of bone diseases |
| Q37969683 | New understanding and treatments for osteoporosis |
| Q37254577 | Nonvertebral fracture risk reduction with nitrogen-containing bisphosphonates |
| Q36283739 | Oral ibandronate: a less frequently administered therapeutic option for postmenopausal osteoporosis |
| Q38489224 | Orthogeriatrics in the management of frail older patients with a fragility fracture |
| Q37155892 | Osteoporosis epidemiology update |
| Q36835357 | Osteoporosis screening for men: are family physicians following the guidelines? |
| Q37686083 | Osteoporosis: impact on health and economics |
| Q35995958 | Osteoporotic fragility fractures in African Americans: under-recognized and undertreated. |
| Q37412244 | Outcome after osteosynthesis of hip fractures in nonagenarians |
| Q36217215 | Parathyroid hormone (1-84) and treatment of osteoporosis |
| Q36711181 | Patient adherence to osteoporosis medications: problems, consequences and management strategies. |
| Q37018957 | Patient preference in the management of postmenopausal osteoporosis with bisphosphonates |
| Q36443755 | Pharmacological treatments for osteoporosis in very elderly people |
| Q36883821 | Physical Functioning Among Women Aged 80 Years and Older With Previous Fracture |
| Q37565638 | Poor adherence to oral bisphosphonate treatment and its consequences: a review of the evidence |
| Q58204050 | Prediction of osteoporosis with dental radiographs and age |
| Q37413731 | Prevalence of osteoporosis in Iran: A meta-analysis |
| Q35188424 | Preventing osteoporotic fractures with bisphosphonates: a review of the efficacy and tolerability |
| Q33974135 | Previous vertebral compression fractures add to the deterioration of the disability and quality of life after an acute compression fracture |
| Q37196002 | Protective effect of total carotenoid and lycopene intake on the risk of hip fracture: a 17-year follow-up from the Framingham Osteoporosis Study |
| Q31112594 | Proximal femoral fractures in the elderly. Data from health insurance providers on more than 23 million insured persons--part 2. |
| Q34695101 | Psoralen stimulates osteoblast differentiation through activation of BMP signaling |
| Q33708822 | Retrospective population cohort study on hip fracture risk associated with zolpidem medication |
| Q36897425 | Risedronate once monthly: a potential new regimen for the treatment of postmenopausal osteoporosis |
| Q34257886 | Risedronate: a review of its pharmacological properties and clinical use in resorptive bone disease |
| Q38440800 | Risk of hip fracture in Addison's disease: a population-based cohort study |
| Q34984177 | Role of zoledronic acid in the prevention and treatment of osteoporosis |
| Q92676575 | Safety Profiles, Pharmacokinetics, and Changes in Bone Turnover Markers After Twice-Weekly Subcutaneous Administration of Teriparatide in Healthy Japanese Postmenopausal Women: A Single-Blind Randomized Study |
| Q48148659 | Sheep model for osteoporosis: sustainability and biomechanical relevance of low turnover osteoporosis induced by hypothalamic-pituitary disconnection. |
| Q51700241 | Shortcomings of DXA to assess changes in bone tissue density and microstructure induced by metabolic bone diseases in rat models. |
| Q40458390 | Southwestern Internal Medicine Conference: Prevention of Hip Fractures in the Elderly |
| Q92489280 | Study of twice-weekly injections of Teriparatide by comparing efficacy with once-weekly injections in osteoporosis patients: the TWICE study |
| Q72127990 | Subsequent hip fracture among older adults |
| Q42975298 | Supplementation of ascorbic acid and alpha-tocopherol is useful to preventing bone loss linked to oxidative stress in elderly |
| Q26863740 | The Chinese skeleton: insights into microstructure that help to explain the epidemiology of fracture |
| Q96641764 | The Effect of Denosumab on Bone Mass in Super Elderly Patients |
| Q92905113 | The Effect of a Screening and Treatment Program for the Prevention of Fractures in Older Women: A Randomized Pragmatic Trial |
| Q37152286 | The Effects of Age, Adiposity, and Physical Activity on the Risk of Seven Site-Specific Fractures in Postmenopausal Women |
| Q50021635 | The Prevalence of Vertebral Fractures Is Associated With Reduced Hip Bone Density and Inferior Peripheral Appendicular Volumetric Bone Density and Structure in Older Women |
| Q41597014 | The crippling consequences of fractures and their impact on quality of life |
| Q73351068 | The diagnostic role of dual femur bone density measurement in low-impact fractures |
| Q40502333 | The economic and human costs of osteoporotic fracture |
| Q43595390 | The effect of age and bone mineral density on the absolute, excess, and relative risk of fracture in postmenopausal women aged 50-99: results from the National Osteoporosis Risk Assessment (NORA). |
| Q34718153 | The efficacy of calcitriol therapy in the management of bone loss and fractures: a qualitative review |
| Q28742188 | The epidemic of hip fractures: are we on the right track? |
| Q41530912 | The epidemiology and pathogenesis of osteoporosis |
| Q30588919 | The epidemiology of osteoporosis--Bone Evaluation Study (BEST): an analysis of routine health insurance data |
| Q51338465 | The human cost of fracture. |
| Q35868424 | The impact of fragility fracture on health-related quality of life : the importance of antifracture therapy |
| Q37430484 | The orthopaedic treatment of fragility fractures. |
| Q37308800 | The relationship between clustering health-promoting components of lifestyle and bone status among middle-aged women in a general population |
| Q45947017 | The relationship between low bone mass and metabolic syndrome in Korean women. |
| Q37738680 | The societal burden of osteoporosis |
| Q38945640 | The standardized creation of a lumbar spine vertebral compression fracture in a sheep osteoporosis model induced by ovariectomy, corticosteroid therapy and calcium/phosphorus/vitamin D-deficient diet. |
| Q38005045 | Therapeutic options for low bone mineral density in HIV-infected subjects |
| Q36892895 | Transdermal hormone therapy and bone health |
| Q36222865 | Transmission of force in the lumbosacral spine during backward falls |
| Q36563407 | Treating osteoporosis with bisphosphonates and addressing adherence: a review of oral ibandronate |
| Q28258998 | Update on bazedoxifene: a novel selective estrogen receptor modulator |
| Q48048858 | Vertebral fractures and their association with health-related quality of life, back pain and physical function in older women |
| Q35107981 | What is osteoporosis? |
| Q79251980 | [Is use of the fixateur externe no longer indicated for the treatment of unstable radial fracture in the elderly?] |
| Q93111114 | miR‑488 negatively regulates osteogenic differentiation of bone marrow mesenchymal stem cells induced by psoralen by targeting Runx2 |
Search more.